TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The week 43 review from Global Cosmetics News describes mixed performance across the beauty industry: P&G and Puig reported sales growth, while China’s online beauty sales fell 6% in September. Regulatory changes, corporate restructuring, retail closures and a production halt in Ukraine also featured. The review does not provide detailed source documentation or independent verification for each development.
Global Cosmetics News’ week 43 review reports contrasting conditions across cosmetics and personal care: P&G recorded 4% sales growth in fiscal Q1 2027 and Puig posted record third-quarter sales, while China’s online beauty sales declined 6% in September. The roundup also identifies regulatory changes, company restructuring and disruptions to retail and manufacturing, offering a snapshot of an industry facing uneven demand and shifting compliance requirements.
The financial picture varied by company and market. According to the review, P&G’s fiscal first-quarter sales rose 4%, with its Beauty division providing support. Puig reported record third-quarter sales, with make-up and Asia-Pacific cited as contributors. Dolce & Gabbana Beauty, meanwhile, set a goal of double-digit growth through international expansion. By contrast, the review says online beauty sales in China fell 6% in September, amid weaker demand for multinational brands and greater competition. It does not specify the comparison period or provide the underlying sales data.
Corporate developments included portfolio changes and investment plans. Unilever sold its Welly bandage brand to Forward Consumer Partners, while Solabia said it would focus operations on cosmetics and nutraceuticals following Muriel Koch’s appointment as CEO. Proya Cosmetics opened a European innovation laboratory in France. The roundup also reports that Malaysia’s Big Caring Pharmacy outlined plans for a US$600 million IPO and that Walmart targeted a US$6.5 billion bond sale to fund retail expansion. Those figures refer to separate proposed financing moves, not completed transactions.
Regulatory and operational news ranged from proposed restrictions on high-risk cosmetic procedures in the UK to an extension of Indonesia’s halal certification deadline for cosmetics and personal care products to 2028. The review says the US FDA cleared a Phase 2 clinical trial investigating injectable PDGF for under-eye hollows; trial clearance does not establish a treatment’s effectiveness or approval for general use. It also reports updated labelling and safety documentation for Kenvue’s Neutrogena acne toner. Retail closures amid civil unrest in France and Milan, and a production halt after damage to Ukrainian personal care manufacturer 2K, underscored the potential impact of events outside the market.
Beauty Firms Face Uneven Demand
The roundup matters because it shows that industry performance cannot be summarized by a single growth trend. Company results diverged: P&G and Puig reported gains, while the reported China decline points to pressure in a major market. Expansion plans and new research facilities suggest some companies are continuing to invest despite that uneven backdrop.
At the same time, rules and operating conditions affect business decisions. Cosmetic-procedure oversight and halal certification deadlines can shape which products and services companies offer, and when they can enter or serve a market. Civil unrest and damage to a manufacturing site also show how retail access and production can be interrupted. The review provides a useful list of developments, but not enough detail to measure their financial impact across the sector.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
A Week Across Markets and Operations
The source is a weekly industry roundup, not a single-company earnings release or a consolidated market report. Its examples span financial results, brand strategy, regulatory compliance, leadership and day-to-day operations. The figures cited cover different periods: P&G’s fiscal Q1 2027, Puig’s third quarter and China’s September online sales. They should not be treated as directly comparable measures.
The review also records several leadership moves: dsm-firmenich appointed Richard Ridinger as chairman, Chanel continued board changes as Bruno Pavlovsky stepped down, Dermalogica CEO Aurelian Lis announced his departure, and L’Oréal named its North Asia CFO to boards of Chinese manufacturing subsidiaries. Brand activity included Maybelline New York appointing Hannah El Zahed as its first brand ambassador in Egypt and a limited-edition lip stain partnership between Virgin and Wonderskin. These items illustrate the breadth of the roundup rather than a single coordinated industry shift.
“The global cosmetics and personal care industry saw developments across financial performance, regulatory oversight and international expansion.”
— Global Cosmetics News, in its week 43 review
Details Behind the Weekly Figures
The source is a summary and does not include the underlying filings, datasets or full regulatory documents for the developments it lists. China’s 6% decline is not accompanied by a stated year-on-year or month-on-month baseline, nor a definition of the online beauty market covered. The review also does not give enough detail to compare P&G’s and Puig’s results on a common basis.
Several items remain at an early or proposed stage. The UK measures are described as proposals, and the financing plans cited for Walmart and Big Caring Pharmacy are not presented as completed sales or listings. The review does not state the trial protocol or results for the PDGF study, or provide details on the circumstances and extent of damage at 2K. Readers should treat these reports as attributed summaries pending fuller company and official disclosures.
Results, Rules and Plans to Watch
Developments to watch include whether the UK government advances its proposed restrictions on high-risk cosmetic procedures and how businesses use Indonesia’s extended certification period ahead of the 2028 deadline. Investors and suppliers will also look for confirmation of the planned bond sale and IPO, while company filings and subsequent earnings releases can add detail to the sales trends cited in the review.
For the clinical research item, the next meaningful update would be information on trial progress and results; FDA clearance to begin a Phase 2 study is not evidence that the injectable is effective or available as a treatment. The status of the disrupted Ukrainian production site and the effects of retail closures are also not specified in the roundup. Further updates from the companies and relevant authorities will be needed to establish outcomes.
Key Questions
What was the main takeaway from the week 43 review?
The roundup describes mixed industry conditions: P&G and Puig reported growth, while China’s online beauty sales were reported down 6% in September. Regulation, corporate changes and operational disruptions also featured.
What does the reported 6% decline in China refer to?
Global Cosmetics News says online beauty sales in China declined 6% in September. The review does not identify the comparison baseline, measurement method or data provider, so the figure should not be interpreted as a year-on-year or month-on-month change without further sourcing.
Did the UK introduce new restrictions on cosmetic procedures?
The review describes proposed tougher restrictions on high-risk cosmetic procedures, including limiting some treatments to qualified healthcare professionals. It does not say the proposals had become law.
Does FDA clearance mean the PDGF treatment is approved?
No. The review says the US FDA cleared a Phase 2 clinical trial investigating injectable PDGF for under-eye hollows. Permission to conduct a trial is not proof of effectiveness or approval for general use.
Which developments remain unconfirmed or incomplete?
The roundup describes proposed regulatory measures and planned financing activity, rather than completed outcomes. It also does not provide follow-up on 2K’s production halt, the extent of retail disruption or detailed results from the PDGF study.
Source: rss
